MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412895 | Name: Cilazaprilat

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cilazaprilat is the active metabolite of cilazapril, a pyridazine angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity.

Chemical Structure

Cilazaprilat
Cilazaprilat
CAS#90139-06-3

Theoretical Analysis

MedKoo Cat#: 412895

Name: Cilazaprilat

CAS#: 90139-06-3

Chemical Formula: C20H27N3O5

Exact Mass: 389.1951

Molecular Weight: 389.45

Elemental Analysis: C, 61.68; H, 6.99; N, 10.79; O, 20.54

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Cilazaprilat; Ro31-3113; Ro-31-3113 Ro 31-3113
IUPAC/Chemical Name
(1S,9S)-9-(((S)-1-carboxy-3-phenylpropyl)amino)-10-oxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
InChi Key
UVAUYSRYXACKSC-ULQDDVLXSA-N
InChi Code
InChI=1S/C20H27N3O5/c24-18-15(8-4-12-22-13-5-9-17(20(27)28)23(18)22)21-16(19(25)26)11-10-14-6-2-1-3-7-14/h1-3,6-7,15-17,21H,4-5,8-13H2,(H,25,26)(H,27,28)/t15-,16-,17-/m0/s1
SMILES Code
OC([C@@H](N[C@H]1CCCN2CCC[C@@H](C(O)=O)N2C1=O)CCc3ccccc3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 389.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Andersson RG, Karlberg BE, Lindgren BR, Persson K, Rosenqvist U. Enalaprilat, but not cilazaprilat, increases inflammatory skin reactions in guinea-pigs. Drugs. 1991;41 Suppl 1:48-53. doi: 10.2165/00003495-199100411-00009. PMID: 1712272. 2: Mombouli JV, Nephtali M, Vanhoutte PM. Effects of the converting enzyme inhibitor cilazaprilat on endothelium-dependent responses. Hypertension. 1991 Oct;18(4 Suppl):II22-9. doi: 10.1161/01.hyp.18.4_suppl.ii22. PMID: 1916998. 3: Kolocouri F, Dotsikas Y, Apostolou C, Kousoulos C, Soumelas GS, Loukas YL. Advantages of automation in plasma sample preparation prior to HPLC/MS/MS quantification: application to the determination of cilazapril and cilazaprilat in a bioequivalence study. J AOAC Int. 2011 May-Jun;94(3):758-64. PMID: 21797003. 4: Prieto JA, Jiménez RM, Alonso RM, Ortiz E. Determination of the antihypertensive drug cilazapril and its active metabolite cilazaprilat in pharmaceuticals and urine by solid-phase extraction and high-performance liquid chromatography with photometric detection. J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):23-34. doi: 10.1016/s0378-4347(00)00580-6. PMID: 11318420. 5: Kleinbloesem CH, van Brummelen P, Francis RJ, Wiegand UW. Clinical pharmacology of cilazapril. Drugs. 1991;41 Suppl 1:3-10. doi: 10.2165/00003495-199100411-00003. PMID: 1712269. 6: Williams PE, Brown AN, Rajaguru S, Walters GE, McEwen J, Durnin C. A pharmacokinetic study of cilazapril in elderly and young volunteers. Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):211S-215S. doi: 10.1111/j.1365-2125.1989.tb03484.x. PMID: 2527535; PMCID: PMC1379750. 7: Williams PE, Brown AN, Rajaguru S, Francis RJ, Walters GE, McEwen J, Durnin C. The pharmacokinetics and bioavailability of cilazapril in normal man. Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):181S-188S. doi: 10.1111/j.1365-2125.1989.tb03480.x. PMID: 2527531; PMCID: PMC1379746. 8: Matoba S, Tatsumi T, Keira N, Kawahara A, Akashi K, Kobara M, Asayama J, Nakagawa M. Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes. Circulation. 1999 Feb 16;99(6):817-22. doi: 10.1161/01.cir.99.6.817. PMID: 9989969. 9: Krum H, Jackson B, Conway EL, Howes LG, Johnston CI, Louis WJ. Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclopenthiazide. J Cardiovasc Pharmacol. 1992 Sep;20(3):451-7. doi: 10.1097/00005344-199209000-00017. PMID: 1279292. 10: Lee HW, Park WS, Cho SH, Kim MH, Seo JH, Kim YW, Kim SS, Lee YS, Lee KT. A liquid chromatography/positive ion tandem mass spectrometry method for the determination of cilazapril and cilazaprilat in human plasma. Talanta. 2007 Jan 15;71(1):62-7. doi: 10.1016/j.talanta.2006.03.020. Epub 2006 Mar 31. PMID: 19071268.